title: PI3Kδ inhibition hits a sensitive spot in B cell malignancies.
abstract: A PI3Kδ-selective inhibitor shows impressive clinical activity in chronic lymphocytic leukemia and indolent B cell non-Hodgkin's lymphomas. In these malignancies, the PI3K pathway is not mutationally activated as in many other cancers, but it is important for mediating supportive cues from the cancer microenvironment and the B cell antigen receptor.
authors.affiliation: UCL Cancer Institute, University College London, 72 Huntley Street, London WC1E 6DD, UK. Electronic address: bart.vanh@ucl.ac.uk.
authors.forename: Bart
authors.initials: B
authors.lastname: Vanhaesebroeck
authors.affiliation: UCL Cancer Institute, University College London, 72 Huntley Street, London WC1E 6DD, UK.
authors.forename: Asim
authors.initials: A
authors.lastname: Khwaja
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000187:drug effects; D002454:Cell Differentiation; D002465:Cell Movement; D049109:Cell Proliferation; D002470:Cell Survival; D058534:Class I Phosphatidylinositol 3-Kinases; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011687:Purines / Q000627:therapeutic use*; D052999:Quinazolinones / Q000627:therapeutic use*; D011947:Receptors, Antigen, B-Cell / Q000378:metabolism; D000069283:Rituximab; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011687:Purines; D052999:Quinazolinones; D011947:Receptors, Antigen, B-Cell; D000069283:Rituximab; D058534:Class I Phosphatidylinositol 3-Kinases; C486018:PIK3CD protein, human; C552946:idelalisib